High-affinity BNA bridged nucleic acid, BNAClamp™, LNA, PNA, and modified oligo synthesis for PCR clamping, mutation detection, SNP discrimination, miRNA analysis, ISH/FISH, antisense research, and diagnostic assay development.
BNA / 2’,4’-BNANC is a third-generation bridged nucleic acid chemistry with a six-membered bridged structure that restricts sugar conformation and promotes stronger Watson-Crick binding to DNA or RNA targets. Bio-Synthesis positions BNA as the primary modified oligo platform while also supporting LNA and other nucleic acid analogs.
Designed for strong target binding, nuclease resistance, and high sequence discrimination.
Each BNA addition can increase duplex Tm, supporting shorter and more specific probes.
Improves DNA/RNA binding and triplex formation for advanced targeting.
Enhanced resistance against exo- and endonuclease degradation.
Ideal when assay success depends on high affinity, mismatch discrimination, and robust detection.
Wild-type suppression and mutant allele enrichment.
Short high-affinity probes for short RNA and tissue detection workflows.
Single-nucleotide mismatch discrimination and allele-specific detection.
BNA is optimized for high-affinity hybridization, mismatch discrimination, and diagnostic assay performance. LNA and PNA provide alternative modified oligo strategies depending on polymerase compatibility, probe format, and targeting requirements.
Why BNA? BNA provides strong duplex stability, mismatch discrimination, and PCR clamp performance while maintaining compatibility with many molecular biology and diagnostic workflows.
BNAClamp™ probes bind strongly to wild-type sequences and suppress their PCR amplification, allowing rare mutant targets to amplify preferentially.
BNAClamp™ binds the wild-type sequence and blocks polymerase extension.
Mismatch prevents strong clamp binding, allowing mutant amplification.
Rare mutation signal becomes easier to detect in qPCR or mutation assays.
BNA can be incorporated with DNA, RNA, LNA and other analogs to support diagnostic, therapeutic research, and molecular biology workflows requiring stronger binding and stability.
BNAClamp™ and BNA probes for wild-type suppression, rare variant enrichment, and mutation-sensitive assays.
High-affinity probes supporting single-base mismatch discrimination and allele-specific assay development.
Short high-affinity probes for robust detection of microRNA targets regardless of GC content.
BNA-enhanced probes for short transcripts, preserved tissue sections, cell preparations, and imaging assays.
Duplex/triplex stabilization for RNA targeting, gene silencing research, antigene, and antisense workflows.
BNA incorporation can improve aptamer stability while preserving target-binding properties.
Bio-Synthesis supports custom BNA, LNA, PNA, DNA/RNA analogs, labels, linkers, purification options, and QC documentation for research and diagnostic development programs.
Modified oligos often require design review around BNA content, target length, Tm balancing, salt form, purification, and analytical release testing.
affinity, Tm, and specificity tuning
BNA can be spiked into DNA or RNA oligonucleotides to tune duplex stability, probe length, mismatch discrimination, and nuclease resistance.
LNA, labels, conjugates, and delivery formats
Bio-Synthesis supports BNA and LNA modified oligos with standard and specialized modifications for assay development.
Review the BNA brochure and comparison resource for chemistry background, performance characteristics, BNAClamp™ technology, applications, and synthesis options.
Bio-Synthesis brochure describing BNA / 2’,4’-BNANC chemistry, BNAClamp™ PCR, miRNA detection, SNP discrimination, synthesis options, purification, and QC.
View Brochure →
Comparison resource for choosing BNA, LNA, PNA, or DNA probes based on affinity, stability, compatibility, probe length, and diagnostic application needs.
View Comparison →
Design recommendations for BNA-based oligonucleotide probes including mismatch discrimination, Tm balancing, probe length, target selection, and diagnostic assay optimization.
View Design Guidelines →
Technical guidance for designing antisense gapmers including wing chemistry selection, central DNA gap length, RNase H activation, mismatch discrimination, and target optimization strategies.
Read Gapmer Design Guide →
BNA and bridged nucleic acid chemistries have been investigated for antisense, gapmer, cholesterol-lowering, and RNA targeting applications due to their enhanced affinity, nuclease resistance, and mismatch discrimination properties.
Wang E. et al. evaluated BNA-based antisense oligonucleotides targeting PCSK9 in diet-induced hypercholesterolemic mice and demonstrated cholesterol-lowering activity.
View Article →
Study describing bridged nucleic acid gapmer design strategies, RNase H activation, and antisense activity optimization.
Reference discussing high-affinity bridged nucleic acid antisense oligonucleotides, stability enhancement, and RNA targeting performance.
Review article covering BNA/LNA chemistry, gapmer architecture, nuclease resistance, and therapeutic antisense development.
Related applications: BNA gapmer and antisense designs are commonly explored for RNase H-mediated silencing, splice modulation, miRNA targeting, cholesterol regulation, and mutation-selective RNA targeting workflows.
Explore connected oligo services for labels, conjugation, probe design, and assay development.
Include sequence, BNA/LNA placement, target, scale, purification, labels, linkers, format, and QC needs.
Request Quote →
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.